LCHINA is the first and only stock market index available to the public that follows China’s biopharma industry from both its regional and U.S. listed perspective.

Loncar Investments, LLC has recently announced the launch of the Loncar China BioPharma Index (LCHINA), the world’s first global benchmark tracking the performance of companies leading China’s biotech revolution.
LCHINA is the first and only stock market index available to the public that follows China’s biopharma industry from both its regional and U.S. listed perspective.
With a focus on innovators, the index contains globally-listed pharmaceutical companies, biotech companies, drug manufacturers, diagnostics companies, wholesalers, distributors and service providers that play a strategic role in growing China’s drug industry.
The index uses a modified equal-weighting methodology that aims to capture both the significant potential of China’s overall biopharma industry and the entrepreneurial spirit of innovators transforming it today.
LCHINA currently has 32 holdings, including Shanghai Fosun Pharmaceutical Group, BeiGene, Genscript Biotech, Zai Lab and Hutchison China MediTech. Index values are reported each day to global index data providers.